Tweets
Follow me today and tomorrow for @RheumNow Live 2023 Coverage!
#RheumTwitter #RNL2023 https://t.co/sS6AoF1Dij
Eric Dein @ericdeinmd ( View Tweet )
3 years 3 months ago
QD Clinic - RheumNow Live 2023 Preview https://t.co/T8VMyrL1Qz https://t.co/E90wsaqwaY
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/sax8iHuljb https://t.co/71zqAzZViV
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Itaconate - A Potential New Immunosuppressive
Researchers have revealed the modulatory effect of the anti-inflammatory metabolite ITA on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.
https://t.co/1kaxHou8pz https://t.co/VLLAzgiYoM
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Happy Match Day! Congratulations to all that have matched. #MATCHDAY2023
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Follow my coverage tomorrow and Sunday!
#RNL2023 RheumNow Live
@RheumNow #RheumTwitter https://t.co/6cZHJxPltA
Eric Dein @ericdeinmd ( View Tweet )
3 years 3 months ago
Multicenter study of 1516 MIS-C pts - Initial Rx: 13% recv anakinra (w/ or w/o) otherdrugs; 64% rx w/ IVIG & steroids, 16%IVIG alone, 4% steroids alone. Anakinra gave no short-term CV benefits over IVIG and glucocorticoids alone. https://t.co/IVaC5dXzs8
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
28 biomarkers studied in 259 SSc-ILD, 179 SSc-NO ILD, 172 IPF & 30 healthy controls. Composite biomarker index (w/ SP-D [surfactant prot. D], Ca15-3 [MUC1], & ICAM-1) strongly correlated w/ SSc-ILD (adj OR 12.7); independent of age, sex, smoking, PFTs https://t.co/F0iKFqcZoY https://t.co/Ao25N1DFIx
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Transcriptomic studies of Rx Refractory #RA pts shows increased gene expression of plasmacytoid dendritic cells (pDC) (reflecting expansion of pDC precursors) correlated well w/ Rx resistance. Type I IFN negatively correlated w pre-DC gene expression https://t.co/japvTnuTNu https://t.co/ad6ofbg3cO
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Open-label trial of Guselkumab (IL-23 inhib) in 20 moderate-to-severe hidradenitis suppurativa (HS) pts saw 65% with HiSCR response at wk 16. Yet phase IIB NOVA PBO-RCT showed GUS HiSCR response 45–51% (vs 39% PBO). GUS may only benefit subgroup of HS https://t.co/OxtFfyRMFk https://t.co/hnQyU0VWxg
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of experts have developed evidence-based points to consider regarding the cost-effective use of b/tsDMARDs in the treatment of inflammatory rheumatic diseases.
https://t.co/jpxQggd89T https://t.co/zjer5QTN3C
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
Optimal Timing of Elective Hip or Knee Arthroplasty
https://t.co/Dz7qHxS5aO https://t.co/z7Q2oReEJs
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 3 months ago
